Loading company…
ID 405089522 · FY 2020–2024 · 5 years
ძირითად საქმიანობას წარმოადგენს ფარმაცევტული და პარაფარმაციის პროდუქტების იმპორტ-ექსპორტი და საბითუმო რეალიზაცია.
Bars are revenue on the left axis; lines are EBITDA and net margin on the right.
| Ratio | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Margins | |||||
| Gross Margin | 63.2% | 68.6% | 71.2% | 74.8% | 73.7% |
| EBITDA Margin | 33.8% | 39.5% | 40.7% | 36.8% | 27.5% |
| EBITDAR | 892 | 1,676 | 2,763 | 3,129 | 3,521 |
| EBITDAR Margin | 34.5% | 40.0% | 41.1% | 37.2% | 27.9% |
| EBIT Margin | 33.7% | 39.4% | 40.7% | 36.7% | 27.3% |
| Net Profit Margin | 30.6% | 37.4% | 38.4% | 31.6% | 23.9% |
| Operating Expense % of Sales | 29.5% | 29.1% | 30.5% | 38.0% | 46.3% |
| Returns | |||||
| Return on Assets (ROA) | 75.1% | 66.7% | 61.6% | 53.1% | 48.4% |
| Return on Equity (ROE) | 92.0% | 74.4% | 66.2% | 62.5% | 51.3% |
| ROIC [EBIT / Invested Capital] | 108.4% | 78.4% | 71.1% | 74.7% | 83.6% |
| Leverage & liquidity | |||||
| Debt-to-Assets | 0.0% | 0.0% | 0.0% | 0.0% | 1.1% |
| Debt-to-Equity | 0.00x | 0.00x | 0.00x | 0.00x | 0.01x |
| Debt-to-EBITDA | 0.00x | 0.00x | 0.00x | 0.00x | 0.02x |
| Equity-to-Assets | 81.6% | 89.7% | 93.1% | 84.9% | 94.4% |
| Net Debt | -57 | -1 | -51 | -121 | -1,749 |
| Cash & Equivalents | 57 | 1 | 53 | 122 | 1,817 |
| Total Debt | N/A | N/A | 2 | 1 | 68 |
| Efficiency & working capital | |||||
| Inventory Turnover | 26.91x | N/A | N/A | N/A | N/A |
| Days Inventory Outstanding (DIO) | 13.6 | N/A | N/A | N/A | N/A |
| Receivables Turnover | 2.74x | 2.74x | 2.31x | 2.76x | 4.50x |
| Days Sales Outstanding (DSO) | 133.1 | 133.0 | 158.2 | 132.3 | 81.0 |
| Payables Turnover | 7.71x | 21.34x | 7.90x | 15.82x | N/A |
| Days Payable Outstanding (DPO) | 47.3 | 17.1 | 46.2 | 23.1 | N/A |
| Cash Conversion Cycle | 99.3 days | 115.9 days | 112.0 days | 109.2 days | 81.0 days |
| Asset Turnover | 2.45x | 1.78x | 1.60x | 1.68x | 2.03x |
| Cash flow & dividends | |||||
| Operating Cash Flow | 435 | 662 | 1,081 | 1,966 | 3,389 |
| Free Cash Flow (OCF − Capex proxy) | 435 | 253 | 797 | 1,880 | 3,386 |
| Cash Conversion (OCF / EBITDA) | 49.9% | 40.0% | 39.5% | 63.6% | 97.8% |
| Dividends Declared | N/A | N/A | N/A | N/A | N/A |
| Dividend Payout Ratio | N/A | N/A | N/A | N/A | N/A |
Money rows — EBITDAR, net debt, cash, total debt, operating and free cash flow, dividends declared — are in ₾ '000. Margins, returns and payout are percentages; turnover and leverage are multiples; DIO/DSO/DPO are days. Hover a metric name for its definition.
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Companies sharing this sub-sector, ranked by how close their latest revenue is to this one — not a curated comp set.
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).
Ownership & directors from companyinfo.ge (public corporate registry).